Targeted elimination of activated hepatic stellate cells by an anti-epidermal growth factor-receptor single chain fragment variable antibody-tumor necrosis factor-related apoptosis-inducing ligand (scFv425-sTRAIL)

Journal of Gene Medicine

Volumn 16, Issue 9-10, 2014, Pages 281-290

  Arabpour, Mohammad ^a   Poelstra, Klaas ^a   Helfrich, Wijnand ^b   Bremer, Edwin ^b   Haisma, Hidde J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

EGFR; Liver fibrosis; Targeted therapy; TRAIL

Indexed keywords

CASPASE; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ACTA2 PROTEIN, HUMAN; ACTIN; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; CASPASE 3; CASPASE 7; COLLAGEN TYPE 1; SCFV 425;

APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STELLATE CELL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM;

ADENOVIRIDAE;

ACTINS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-CHAIN ANTIBODIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84926627395     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2776     Document Type: Article

References (28)

1. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21: 311-335.
2. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451.
3. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939.
4. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124: 445-458.
5. Janoschek N, van de Leur E, Gressner AM, Weiskirchen R. Induction of cell death in activated hepatic stellate cells by targeted gene expression of the thymidine kinase/ganciclovir system. Biochem Biophys Res Commun 2004; 316: 1107-1115.
6. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273-278.
7. Abriss B, Hollweg G, Gressner AM, Weiskirchen R. Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. J Hepatol 2003; 38: 169-178.
8. Puche JE, Lee YA, Jiao J, et al. A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage. Hepatology 2013; 57: 339-350.
9. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95.
10. Berasain C, Perugorria MJ, Latasa MU, et al. The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) 2009; 234: 713-725.
11. Reinehr R, Sommerfeld A, Häussinger D. CD95 Ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 2008; 134: 1494-1506.
12. Tugues S, Fernandez-Varo G, Munoz-Luque J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
13. Kenny PA. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opin Ther Targets 2007; 11: 1287-1298.
14. Perugorria MJ, Latasa MU, Nicou A, et al. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 2008; 48: 1251-1261.
15. Saito Y, Haendeler J, Hojo Y, Yamamoto K, Berk BC. Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation. Mol Cell Biol 2001; 21: 6387-6394.
16. Bremer E, Samplonius DF, van Genne L, et al. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv: sTRAIL fusion protein with specificity for human EGFR. J Biol Chem 2005; 280: 10025-10033.
17. Bremer E, van Dam GM, de Bruyn M, et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008; 16: 1919-1926.
18. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv: sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer 2004; 109: 281-290.
19. Duiker EW, de Vries EG, Mahalingam D, et al. Enhanced antitumour efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 2009; 15: 2048-2057.
20. Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc 2007; 2: 1236-1247.
21. Haisma HJ, Kamps JA, Kamps GK, Plantinga JA, Rots MG, Bellu AR. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J Gen Virol 2008; 89: 1097-1105.
22. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumour cells by human NK cells. J Immunol 1999; 163: 5358-5366.
23. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-1308.
24. Tarrats N, Moles A, Morales A, Garcia-Ruiz C, Fernandez-Checa JC, Mari M. Critical role of tumour necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodelling, and liver fibrogenesis. Hepatology 2011; 54: 319-327.
25. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumour necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology 2006; 130: 435-452.
26. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407: 810-816.
27. Francois H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 2004; 18: 926-928.
28. Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 158-167.